79617-95-1

Basic information

• Product Name: 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-
• Synonyms: 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-;(1R,4R)-rel-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl -1-naphthalenamine;cis-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl -1-naphthalenamine.;rac-cis-Sertraline;rac-cis-Sertraline Hydrochloride;(1R,4R)-rel-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-Methyl -1-naphthalenaMine Hydrochloride;cis-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro -N-Methyl-1-naphthalenaMine Hydrochloride;Sertraline EP IMpurity G
• CAS NO: 79617-95-1
• Molecular Formula: C₁₇H₁₇Cl₂N
• Molecular Weight: 342.69052
• Product Categories: All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Amines;Aromatics
• Mol File: 79617-95-1.mol
• Article Data: 11

Chemical Properties

• Melting Point: 270-273?C
• Appearance: /
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• CAS DataBase Reference: 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-(79617-95-1)
• EPA Substance Registry System: 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-(79617-95-1)

Safety Data

• Hazardous Substances Data: 79617-95-1(Hazardous Substances Data)

Usage

Description

4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydrois a chemical compound that acts as a potent and selective inhibitor of serotonin uptake. It is a pale yellow oil and is structurally related to Sertraline, which is a selective serotonin reuptake inhibitor (SSRI) used as an antidepressant.

Uses

Used in Pharmaceutical Industry:
4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydrois used as an antidepressant for the treatment of depression and other mood disorders. It functions by inhibiting the reuptake of serotonin, a neurotransmitter that plays a crucial role in regulating mood, thereby increasing its availability in the synaptic cleft and enhancing its signaling.
Used in Research Applications:
4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydrois also used as a research tool in the study of serotonin receptors and their role in various physiological and pathological processes. Its potent and selective inhibition of serotonin uptake makes it a valuable compound for investigating the mechanisms of action and potential therapeutic applications of SSRIs.
Used in Drug Development:
4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydromay be utilized in the development of new drugs targeting serotonin receptors for the treatment of various conditions, including depression, anxiety, and other mood disorders. Its chemical properties and inhibitory effects on serotonin uptake make it a promising candidate for further research and development in the pharmaceutical industry.

Upstream product

• 6284-79-3 3,4-dichlorobenzophenone 
• 79560-19-3 4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one 
• 79560-17-1 4-(3,4-dichlorophenyl)-4-phenylbut-3-enoic acid 
• 74-89-5 methylamine 
• 18282-59-2 4-bromo-1,2-dichlorobenzene 
• 71-43-2 benzene 
• 151169-75-4 3,4-dichlophenylboronic acid 
• 90-15-3 α-naphthol 
• 95-50-1 1,2-dichloro-benzene 
• 79617-89-3 cis-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine hydrochloride 
• 79560-16-0 3-(ethoxycarbonyl)-4-(3,4-dichlorophenyl)-4-phenylbut-3-enoic acid 
• 374778-33-3 [4-(3,4-dichlorophenyl)-4-phenyl-butyryl]-carbamic acid methyl ester 
• 848130-45-0 [4-(3,4-dichlorophenyl)-4-phenylbutyryl]carbamic acid methyl ester 
• 149620-65-5 4-(3,4-dichlorophenyl)-4-phenylbutyric acid 

Downstream Products

• 244223-89-0 (cis-1S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine (R)-mandelate 
• 79617-96-2 Sertraline 
• 79617-98-4 (1R,4R)-sertraline 

Relevant articles and documents

Sertraline racemate and enantiomer: Solid-state characterization, binary phase diagram, and crystal structures

The racemate and enantiomer of sertraline free base were prepared and characterized. The crystalline sertraline enantiomer is relatively less polymorphic compared with the sertraline-HCl salt. The solid-state nature of sertraline racemate was identified to be a racemic compound through a binary melting point phase diagram and spectroscopy analysis. The crystal structures of the racemate and enantiomer were determined to be monoclinic P121/n1 and P21, respectively.

Palladium-Catalyzed Dearomative syn-1,4-Carboamination with Grignard Reagents

A protocol for palladium-catalyzed dearomative functionalization of simple, nonactivated arenes with Grignard reagents has been established. This one-pot method features a visible-light-mediated [4+2] cycloaddition between an arene and an arenophile, and subsequent palladium-catalyzed allylic substitution of the resulting cycloadduct with a Grignard reagent. A variety of arenes and Grignard reagents can participate in this process, forming carboaminated products with exclusive syn-1,4-selectivity. Moreover, the dearomatized products are amenable to further elaborations, providing functionalized alicyclic motifs and pharmacophores. For example, naphthalene was converted into sertraline, one of the most prescribed antidepressants, in only four operations. Finally, this process could also be conducted in an enantioselective fashion, as demonstrated with the desymmetrization of naphthalene.

MANGANESE (III) CATALYZED C--H AMINATIONS

Reactions that directly install nitrogen into C—H bonds of complex molecules are significant because of their potential to change the chemical and biological properties of a given compound. Selective intramolecular C—H amination reactions that achieve high levels of reactivity, while maintaining excellent site-selectivity and functional-group tolerance is a challenging problem. Herein is reported a manganese perchlorophthalocyanine catalyst [MnIII(ClPc)] for intermolecular benzylic C—H amination of bioactive molecules and natural products that proceeds with unprecedented levels of reactivity and site-selectivity. In the presence of Br?nsted or Lewis acid, the [MnIII(ClPc)]-catalyzed C—H amination demonstrates unique tolerance for tertiary amine, pyridine and benzimidazole functionalities. Mechanistic studies indicate that C—H amination proceeds through an electrophilic metallonitrene intermediate via a stepwise pathway where C—H cleavage is the rate-determining step of the reaction. Collectively these mechanistic features contrast previous base-metal catalyzed C—H aminations.